Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Background KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an
aggressive disease with 3-year event-free survival below 40%. Most relapses occur during …

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …

PURPOSE Despite contemporary treatment, up to 10% of children with acute lymphoblastic
leukemia still experience relapse. We evaluated whether a higher dosage of PEG …

Contemporary paediatric clinical trials have improved 5-year event-free survival above 85%
and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in …

We evaluated clinical significance of recently identified subtypes of acute lymphoblastic
leukemia (ALL) in 598 children treated with minimal residual disease (MRD)–directed …

Measurable residual disease (MRD) is highly prognostic for relapse and overall survival
(OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD …

The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …

Background Vincristine plus dexamethasone pulses are generally used throughout
maintenance treatment for childhood acute lymphoblastic leukaemia. However, previous …